Next Article in Journal
Successful Treatment of Gastrointestinal Mucormycosis in an Adult with Acute LeukemiA: Case Report and Literature Review
Previous Article in Journal
Nasopharyngeal Non-Intestinal-Type Adenocarcinoma: A Case Report and Updated Review of the Literature
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Open AccessArticle

Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma

by 1,*, 2,3, 4 and 2,3
1
Telfer School of Management, University of Ottawa, Ottawa, ON, Canada
2
Ivey Business School, Western University, London, ON, Canada
3
Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, London, ON, Canada
4
Department of Medicine, Division of Hematology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(1), 6-14; https://doi.org/10.3747/co.24.3369
Received: 3 November 2016 / Revised: 4 December 2016 / Accepted: 5 January 2017 / Published: 1 February 2017
Background: We conducted a cost-effectiveness analysis of brentuximab vedotin for the treatment of relapsed and refractory Hodgkin lymphoma (hl) in the post–autologous stem-cell transplantation (asct) failure period, from the perspective of the Canadian health care payer. Methods: We developed a decision-analytic model to simulate lifetime costs and benefits of brentuximab vedotin compared with best supportive care for the treatment of patients with hl after failure of asct. Administrative data from Ontario were used to set the model parameters. Results: In the base case, treatment with brentuximab vedotin resulted in incremental quality-adjusted life-years (qalys) of 0.544 and an incremental cost of $89,366 per patient, corresponding to an incremental cost-effectiveness ratio (icer) of $164,248 per qaly gained. The icer was sensitive to the cost of brentuximab vedotin, the hazard ratio used to assess the efficacy of brentuximab vedotin treatment, and health state utilities. Conclusions: In light of the available information, brentuximab vedotin has an icer exceeding $100,000 per qaly gained, which is a level often classified as having “weak evidence for adoption and appropriate utilization” in Canada. However, it is worth noting that provincial cancer agencies take into account not only the costs and associated icer, but also other factors such as a lack of alternative treatment options and the clinical benefits of expensive cancer drugs. Pricing arrangements should be negotiated, and risk-sharing agreements or patient access schemes should be explored.
Keywords: Hodgkin lymphoma; brentuximab vedotin; cost-effectiveness analyses; Markov models Hodgkin lymphoma; brentuximab vedotin; cost-effectiveness analyses; Markov models
MDPI and ACS Style

Babashov, V.; Begen, M.A.; Mangel, J.; Zaric, G.S. Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma. Curr. Oncol. 2017, 24, 6-14. https://doi.org/10.3747/co.24.3369

AMA Style

Babashov V, Begen MA, Mangel J, Zaric GS. Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma. Current Oncology. 2017; 24(1):6-14. https://doi.org/10.3747/co.24.3369

Chicago/Turabian Style

Babashov, V.; Begen, M.A.; Mangel, J.; Zaric, G.S. 2017. "Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma" Curr. Oncol. 24, no. 1: 6-14. https://doi.org/10.3747/co.24.3369

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop